Long-acting paliperidone palmitate - Interim results of an observational study of its effect on hospitalization

International Clinical Psychopharmacology

Volumn 29, Issue 4, 2014, Pages 229-234

  Taylor, David ^a,b   Olofinjana, Olubanke ^a  

^a SOUTH LONDON AND MAUDSLEY NHS FOUNDATION TRUST   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

antipsychotic; long acting injection; paliperidone; schizophrenia

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; PALIPERIDONE; DELAYED RELEASE FORMULATION; ISOXAZOLE DERIVATIVE; NEUROLEPTIC AGENT; PALMITIC ACID DERIVATIVE;

ADULT; AGED; ARTICLE; BIPOLAR DISORDER; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HOSPITAL ADMISSION; HOSPITAL COST; HOSPITALIZATION; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; UNSPECIFIED SIDE EFFECT; VERY ELDERLY; COHORT ANALYSIS; DELAYED RELEASE FORMULATION; DRUG MONITORING; ELECTRONIC MEDICAL RECORD; FOLLOW UP; HOSPITAL; MIDDLE AGED; PATIENT ATTITUDE; PATIENT COMPLIANCE; PSYCHOTIC DISORDERS; RECURRENT DISEASE; UNITED KINGDOM; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; COHORT STUDIES; DELAYED-ACTION PREPARATIONS; DRUG MONITORING; ELECTRONIC HEALTH RECORDS; FEMALE; FOLLOW-UP STUDIES; HOSPITALS, URBAN; HUMANS; ISOXAZOLES; LENGTH OF STAY; LONDON; MALE; MIDDLE AGED; PALMITATES; PATIENT ACCEPTANCE OF HEALTH CARE; PATIENT COMPLIANCE; PSYCHOTIC DISORDERS; RECURRENCE; SCHIZOPHRENIA; YOUNG ADULT;

EID: 84902152300     PISSN: 02681315     EISSN: 14735857     Source Type: Journal    
DOI: 10.1097/YIC.0000000000000028     Document Type: Article

References (15)

1. Bowskill SV, Handley SA, Fisher DS, Flanagan RJ, Patel MX (2012). Risperidone and total 9-hydroxyrisperidone in relation to prescribed dose and other factors: data from a therapeutic drug monitoring service, 2002-2010. Ther Drug Monit 34:349-355.
2. Castberg I, Spigset O (2005). Serum concentrations of risperidone and 9- hydroxyrisperidone after administration of the long-acting injectable form of risperidone: evidence from a routine therapeutic drug monitoring service. Ther Drug Monit 27:103-106. (Pubitemid 40189982)
3. Department of Health (2013). Reference costs guidance for 201213. Available at: https://www.gov.uk/government/uploads/system/uploads/attachment- data/file/ 217040/2012-13-reference-costs-guidance.pdf. [Accessed 9 December 2013].
4. Hogarty GE, Schooler NR, Ulrich R, Mussare F, Ferro P, Herron E (1979). Fluphenazine and social therapy in the aftercare of schizophrenic patients: relapse analyses of a two-year controlled study of fluphenazine decanoate and fluphenazine hydrochloride. Arch Gen Psychiatry 36: 1283-1294. (Pubitemid 11145664)
5. Leucht S, Pitschel-Walz G, Abraham D, Kissling W (1999). Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizophr Res 35:51-68. (Pubitemid 29023554)
6. Niaz OS, Haddad PM (2007). Thirty-five months experience of risperidone longacting injection in a UK psychiatric service including a mirror-image analysis of in-patient care. Acta Psychiatr Scand 116:36-46. (Pubitemid 46889775)
7. Novick D, Haro JM, Bertsch J, Haddad PM (2010). Incidence of extrapyramidal symptoms and tardive dyskinesia in schizophrenia: thirty-six-month results from the European schizophrenia outpatient health outcomes study. J Clin Psychopharmacol 30:531-540.
8. Rosenheck RA, Krystal JH, Lew R, Barnett PG, Fiore L, Valley D, et al. (2011). Long-acting risperidone and oral antipsychotics in unstable schizophrenia. N Engl J Med 364:842-851.
9. Rubio G, Martinez I, Ponce G, Jimenez-Arriero MA, Lopez-Munoz F, Alamo C (2006). Long-acting injectable risperidone compared with zuclopenthixol in the treatment of schizophrenia with substance abuse comorbidity. Can J Psychiatry 51:531-539. (Pubitemid 44166341)
10. Taylor DM, Young C, Patel MX (2006). Prospective 6-month follow-up of patients prescribed risperidone long-acting injection: factors predicting favourable outcome. Int J Neuropsychopharmacol 9:685-694. (Pubitemid 46122768)
11. Taylor D, Fischetti C, Sparshatt A, Thomas A, Bishara D, Cornelius V (2009a). Risperidone long-acting injection: a 6-year mirror-image study of healthcare resource use. Acta Psychiatr Scand 120:97-101.
12. Taylor DM, Fischetti C, Sparshatt A, Thomas A, Bishara D, Cornelius V (2009b). Risperidone long-acting injection: a prospective 3-year analysis of its use in clinical practice. J Clin Psychiatry 70:196-200.
13. Taylor M, Currie A, Lloyd K, Price M, Peperell K (2008). Impact of risperidone long acting injection on resource utilization in psychiatric secondary care. J Psychopharmacol 22:128-131. (Pubitemid 351322859)
14. Tiihonen J, Haukka J, Taylor M, Haddad PM, Patel MX, Korhonen P (2011). A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. Am J Psychiatry 168:603-609.
15. Young CL, Taylor DM (2006). Health resource utilization associated with switching to risperidone long-acting injection. Acta Psychiatr Scand 114:14-20. (Pubitemid 43885480)